Inclusion Criteria:  Age ≥18 years at diagnosis Diagnosed with hereditary ATTR-CM, mixed phenotype Treated with tafamidis (VYNDAQEL 80 mg [four 20-mg tafamidis meglumine capsules] orally once daily or VYNDAMAX 61 mg [one 61-mg tafamidis capsule] orally once daily) for ≥12 months Have had ≥1 pre- and ≥2 post-treatment neurologic assessments  Exclusion Criteria:  History of organ transplant Wild-type TTR genotype Individuals who are non-ambulatory Prior treatment with any disease-modifying therapy (investigational or approved) alone or in combination, except tafamidis, as either VYNDAQEL 80 mg (four 20-mg tafamidis meglumine capsules) orally once daily or VYNDAMAX 61 mg (one 61-mg tafamidis capsule) orally once daily Peripheral neuropathy attributed to causes other than ATTR amyloidosis (e.g., diabetes mellitus, B12 deficiency, HIV infection)